Subscribe
shutterstock_1396957739_pavel_kapysh
Pavel Kapysh / Shutterstock.com
4 February 2020AmericasSarah Morgan

Idenix $2.5bn ruling will impede innovation, says Amgen

Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.

More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility